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SterilizationA permanent contraceptive method that avoids abdominal incisions and general anesthetic should be safer than
sterilization by laparoscopy or laparotomy. In theory, the transcervical route ought to be ideal for female
sterilization. However, past attempts have not seen widespread success, and contemporary efforts demonstrate
that challenges to the creation of an ideal transcervical sterilization technique continue to exist. After 6 years of
use, clinical data and real-world experience indicate that the Essure permanent birth control system is a viable
option. Efficacy of 99.74% has been demonstrated. Adverse effects and risks are low. Patient satisfaction is high.
Successful placement is observed inworldwidemarketing. It can be placed in the office setting, which offsets the
relatively high cost of the device. Recent data suggest that patients and surgeons are choosing hysteroscopic
sterilization over laparoscopic and postpartum sterilization. Adiana emerged in 2009 as a second hysteroscopic
sterilization option. Challenges continue to exist for transcervical sterilization. Compliance with post-procedure
confirmation imaging is not universal. Real-world contraception failures are seen in a setting of protocol non-
compliance. However, extrapolation of the failure rates in real-world use seems to be comparable with other
laparoscopic and abdominal sterilization methods.
© 2009 Published by Elsevier Ireland Ltd. on behalf of International Federation of Gynecology and Obstetrics.1. Introduction
Female sterilization is the single most prevalent method of contra-
ception in the world [1]. United Nations data for 2007 show that of the
1.1 billion partnered women practicing contraception, 20% were using
female sterilization. The next most prevalent modern methods were
intrauterinedevices (16%), oral contraceptives (9%), condoms (6%),male
sterilization (3%), and injectable hormones (3%). Permanent female
contraception routinely entails exposingwomen to abdominal incisions,
and thus to the related risks of surgery andanesthesia. Although they are
generally extremely safe, the traditional methods for sterilization in
women carry risks for major complications, including mortality [2]. A
permanent contraceptive method that avoids abdominal incisions and
general anesthesia should be safer than sterilization by laparoscopy or
laparotomy. In theory, the transcervical routeought tobe ideal for female
sterilization. However, past attempts have not seenwidespread success,
and contemporary efforts demonstrate the challenges remaining for an
optimal method to accomplish tubal occlusion transcervically.
1.1. History: Electrosurgical energy
Cooper [3] presented a detailed history of transcervical steriliza-
tion in 1992. First attempted in the 1920s [4], hysteroscopicty of Michigan Medical Center,
lsevier Ireland Ltd. on behalf of Inteapplication of electrocautery to cause infertility saw a resurgence
in the 1970s. Quinones et al. [5] performed over 1200 hysteroscopic
sterilizations with tubal endocoagulation and observed a bilateral
occlusion rate of 80%. No pregnancies occurred after 1 year of ob-
servation in 513 patients whose hysterosalpingogram had shown
bilateral occlusion. However, of 423 patientsmonitored for 5 years in
whom the hysterosalpingogram had demonstrated occlusion, 3.8%
eventually became pregnant [3]. A subsequent collaborative series
showed a 3.2% pregnancy rate among patients with a hysterosalpin-
gogram showing occlusion, and a 3.2% major complication rate,
including a death after bowel injury [6].
1.2. History: Mechanical devices
Manymechanical devices for tubal occlusion have been proposed
or tried in animals and humans, with limited success. Tube-occluding
substances have included hydrogel/nylon (P-block) [7]; silicone
Ovabloc [8]; polyethylene [9]; nylon [10]; and polytetrafluoroethy-
lene [11].
1.3. History: Chemical
Quinacrine hydrochloride has been studied extensively. Quinacrine
can be instilled blindly or hysteroscopically. It causes inflammation and
subsequent scar tissue formation within the fallopian tubes. Over
100 000 quinacrine sterilization procedures have been performed
worldwide, but the technique is marred in controversy [12].rnational Federation of Gynecology and Obstetrics.
Fig. 1. Essure design.
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Many of thesemethods are available options for womenworldwide.
However, none sees widespread use. Kerin [13] cites improvements in
the design and application of fallopian tube cannulation devices used for
infertility treatments as the foundation for the creation of successful
transcervical sterilization techniques. Catheter technology has ad-
vanced adequately to be able to reliably negotiate an occluding sub-
stance into the fallopian tubes. Cooper [3] identifies that, in the past,
mechanical devices failed because they migrated or were expelled too
frequently. He emphasizes that in order to anchor an implant for tubal
occlusion, one must take advantage of the less-compliant uterine por-
tion of the fallopian tube. Some past failures occurred because the
implanted medium did not result in complete tubal occlusion. Some
devices were temporary; others did not adhere closely enough to the
tubal endothelium to provide adequate occlusion.
2. Essure system
The Essure Permanent Birth Control system (Conceptus; Mountain
View, CA, USA) was marketed first in Australia and Singapore.
Approval by the European Union followed in 2001, and by the United
States Food and Drug Administration late in 2002. It is now also
available across North, Central, and South America, and in parts of Asia
and the Middle East.
2.1. Design
The micro-insert is made of a flexible stainless steel inner coil,
surrounded by a dynamic outer coil composed of nickel titanium
(Nitinol). Polyethylene terephthalate (PET) fibers run along andFig. 2. Placementhrough the inner coil. (Fig. 1) In its expanded form, the implant is
about 4 cm long and up to 2 mm in diameter. The disposable delivery
system includes a nitinol delivery wire, a release catheter, a hydro-
philic delivery catheter, and a handle with mechanisms to retract the
release catheter and the delivery catheter. Thematerials that compose
the micro-insert have a long history of use in medical and surgical
devices. For example, Dacron (Invista; Charlotte, NC, USA), a polyester
made of PET fibers, has been used in suture, grafts, and stents for
about 40 years. Tubal occlusion occurs because of tissue reaction
toward the presence of the PET fibers. The stainless steel-nickel
titanium coil serves as an anchor within the utero-tubal junction,
which keeps the PET fibers in the proper location for tissue in-growth
to occur following placement. The PET fibers elicit a benign local
inflammatory response, which peaks between 2 and 3 weeks after
placement. This inflammatory response gradually resolves over a
10-week period.
2.2. Placement
Placement of the Essure micro-coils requires a rigid hysteroscope
with a 5-Fr operating channel. Most commercially available hystero-
scopes have a 5.5 mm outer diameter operating sheath with inflow
and outflow ports for a fluid distending medium. Warmed normal
saline is typically used for distension. After performing diagnostic
hysteroscopy, and confirming that bilateral placement is possible, the
catheter is introduced under direct visualization into a fallopian tube.
Delivery and release catheters are retracted, and the coil expands to
anchor itself in the tube. After detaching the implant from a guide
wire, the micro-coil spans the utero–tubal junction. Part of the micro-
coil trails into the uterine cavity, and the rest of the coil remains
within the fallopian tube (Fig. 2).t procedure.
Fig. 3. Hysterosalpingogram showing proper implant location and bilateral occlusion.
Fig. 4. Expulsion of implant from left side.
Fig. 5. Tubal patency on right.
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After placement, the patient must practice reliable contraception
for at least 3 months. Sterilization does not occur until the PET fibers
cause local tissue in-growth, which occludes the tubes. Hysterosal-
pingography (HSG) is performed 3 months after placement to dem-
onstrate proper coil location across the utero–tubal junction, and to
demonstrate tubal occlusion. A patient should not rely on the system
for contraception until she has a hysterosalpingogram that shows that
these criteria have been met (Fig. 3).
3. Essure literature review
Over 2500 patients have undergone the procedure as part of a
clinical trial. The subsequent review focuses on the Phase II and Phase III
(Pivotal) FDA clinical trials [14,15].
3.1. Phase II and pivotal trial summary
Together, the trials enrolled 745women (227 Phase II, 518 Pivotal)
in prospective multicenter, international, single-arm trials conducted
between 1998 and 2001. All of the patients were parous, with a mean
age of 32 years. The procedures were performed under paracervical
block, some with intravenous sedation, and some with non-steroidal
anti-inflammatory drugs (NSAIDs). Office and telephone follow-up
occurred at frequent intervals to assess for adverse events, and to
evaluate patient satisfaction. All of the patients practiced alterna-
tive contraception until they underwent HSG 3 months after their
procedure. The length of time of the procedure ranged from 13 to
18 minutes. The recovery time ranged from 30 to 44 minutes.
3.2. Placement success
In the Pivotal Trial [15], the surgeons encountered uterine cavity
pathology that precluded a placement attempt in 2% of the patients. If
one includes all patients who intended to undergo the procedure in the
denominator (intent-to-treat group), bilateral placement was achieved
in 86% of patients in the first procedure. Many patients underwent a
second procedure, which brought bilateral placement up to 90%. The
clinical trials and this author's experience show that several factors can
contribute to placement failure. Tubal spasm, a frequently-encountered
hindrance to cannulating a tube, can be overcome by warming the
distensionmedium, and by administering anNSAIDpreoperatively. Pre-
existing tubal stenosis canbeencountered. Extremely lateral tubes and a
very retroverted uterus make the path to the tubal ostium difficult. A
visual field compromised by bleeding can be avoided by preparing the
endometrium with hormonal contraceptives, and by avoiding unne-
cessary cervical manipulation with uterine dilators or uterine sounds.
Most multiparous cervices do not require dilation prior to passing a 5.5-
mm hysteroscope.3.3. Adverse events
Adverse events or side effects occurred in 3% of patients on the day of
the procedure. These included vasovagal responses, hypervolemia,
cramping, nausea, and vaginal spotting. Except for one patientwhowas
observed overnight for a reaction to narcotics, all of the patients were
discharged home on the same day. During the first year of observation,
the following adverse effects were reported most commonly: back pain
(9%); abdominal cramps (3.8%); dysmenorrhea (2.9%); and pelvic pain
(2.5%). A comparison with traditional female sterilization techniques
emphasizes the better safety profile observed by avoiding abdominal
incision. Major complications—conversion to laparotomy, blood trans-
fusion, febrile morbidity, rehospitalization—occur in 0.9% to 1.6% of
traditional female sterilization surgeries [2]. A mortality rate of 1–4 per
100 000 has been estimated. In the Pivotal Trial, perforation through
the fallopian tube occurred in 1% of patients. Perforation is usually
asymptomatic, recognized only at HSG. Hysteroscopic sterilization also
compares favorably with vasectomy. Minor complications—wound
infection, bleeding, hematoma, granuloma formation, epididymitis—
have been observed in 5% to 10%of vasectomyprocedures. Late sequelae
include chronic testicular pain in almost 1% of patients [16].
3.4. Interpretation of the hysterosalpingogram
Expulsion of the micro-coil from the uterus, or migration of the im-
plant from an acceptable location within the tube, occurred in 3% of
patients. Fig. 4 shows expulsion of the micro-coil from the left side. HSG
demonstrates tubal patency in about 4% of patients at 3 months, despite
proper implant location. Fig. 5 shows tubal patencyon the right side. Some
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fiberswithin themicro-coil. At 6-monthHSG, all patientswith proper coil
locationdemonstratedoccluded tubes. Becausepropermicro-coil location
has correlated with tubal occlusion in clinical trials, some surgeons avoid
performing HSG when alternative imaging (flat plate, sonography)
confirms proper location. Outside of the United Sates, post-Essure HSG
is not routinely performed in all countries.
3.5. Reliance rate
Requiring HSG after hysteroscopic sterilization not only sets this
new procedure apart from laparoscopic sterilization and laparotomy
sterilization, it also entails some new definitions. The “reliance rate” is
defined with the denominator of patients in whom bilateral place-
ment is achieved. The numerator is patients who undergo HSG and
show proper micro-coil location and tubal occlusion. This number
demonstrates that approximately 3% of the time, properly placed coils
migrate or are expelled after initial placement.
3.6. Summary
A summary of the data from the trials that led to FDA approval of
Essure points out several challenges to hysteroscopic sterilization. Two
percent of those who intended to use Essure had no attempt at coil
placement because of uterine cavity pathology. After one procedure,
86% bilateral placement was achieved. After a second procedure,
bilateral placement increased to 90%. Some patients had to wait up to
6 months until they could rely on the procedure. Three percent of
patients could never rely on the procedure because of impropermicro-
implant location. Finally, if one defines the intent-to-treat group as all
the patients who undergo a hysteroscopy to have Essure coils placed,
13% of them ultimately had to choose a different method of contra-
ception. Failure to achieve bilateral device placement remains the
most common factor necessitating an alternate contraception choice.
3.7. Post-approval placement trials
Several clinical trials demonstrate improved bilateral placement
rates. Kerin et al. [17] reported on 109 patients recruited after the
Pivotal study. With more experience, and a redesigned outer delivery
catheter, he achieved 98% bilateral placement after one procedure.
Mino et al. [18] reported 96% bilateral placement in one procedure,
and 98% after a second. The FDA linked its approval of Essure to
subsequent enrollment of 800 patients in a clinical trial with 40 new
surgeons performing the procedure. This Post-Approval Study, not yet
published, demonstrated 94.6% bilateral placement.
4. Essure efficacy
Discussion of contraceptive effectiveness points out another way
that the unique features of this hysteroscopic sterilization procedure
differentiate it from traditional female sterilization. “Effectiveness” is
defined in clinical trials as a lack of pregnancies in women who have
achieved bilateral placement, and have had a confirmatory hyster-
osalpingogram showing proper micro-coil location and occluded
tubes. When patients have met the criteria to rely on Essure, no
known pregnancy has occurred in clinical trials to date. Using an
adjusted indirect method to calculate effectiveness, similar to that in
the CREST trial [2], 5-year data show an efficacy rate of 99.74%.
4.1. Effectiveness: Consumer use
Through October 2008 there had been 258 Essure-related preg-
nancies reported to Conceptus. Scrutiny of thesepregnancies shows that
they have occurred in a variety of patients who did notmeet the criteria
to be able to rely on Essure. Levy et al. [19] analyzed a subset of thesepregnancies and described the factors associated with failure. Patient
non-compliance represents themost common factor. Some patients did
not practice alternative contraception during the 3 months following
placement. Some patients did not present for HSG. There were some
luteal phase pregnancies. A small number of pregnancies were at-
tributed to “physician non-compliance.” That is, a physician recom-
mended reliance on Essure when the defined criteria were not met.
Particularly troublesome is that in 18 of 64 pregnancies, review showed
that the hysterosalpingogram had not been interpreted correctly. A
specific protocol has now been developed for the performance of and
interpretation of the post-placement hysterosalpingogram. Levy points
out that, especially when the surgeonwho places the Essuremicro-coils
is not involved in the HSG, it is important to make sure that the HSG
team is familiarwith the protocol. This author is continually surprised at
the number of ways a post-Essure hysterosalpingogram can be a
challenge to interpret.
4.2. Effectiveness: Extrapolation
An estimate of the number of procedures performed worldwide can
be assumed from the number of procedure kits shipped. Through
October 2008, about 242 263 units had been shipped. One can
extrapolate a commercial-use failure rate from the known numbers of
pregnancies and the procedures performed. A total of 258 pregnancies
among 242 263 procedures suggests a failure rate of about 1.06 per
1000. Real-world use of Essure demonstrates that patients who intend
to use it for contraceptionwill experience pregnancy—whether because
of patient or physician non-compliance, or device failure. Traditional
sterilization procedures are not routinely followed by HSG. It may be
useful for surgeons and patients to compare the rate of pregnancy after
Essurewith the rate of pregnancy after laparoscopic sterilization. This is
at least as favorable as the reported failure in CREST [2].
5. Essure cost analysis
In 2008, the Essure system (one pair of micro-coils and disposable
insertion devices) cost US $1300 in theUnited States. Although this new
technology is expensive, a cost saving is realized in shorter procedure
times, and often, in avoidance of the operating room via office
placement. A retrospective look at the cost of laparoscopic sterilization
in an operating room comparedwith Essure in an office setting showed
Essure to be less expensive [20]. The total cost of a sterilization
procedure was US $2050 for laparoscopy, and US $1374 for Essure.
Avoiding the operating room eliminated the cost of hospital staff
salaries, room time, supplies, and anesthesiology services. The cost of
the surgeon's time was slightly less also. Even a comparison of hospital
laparoscopic sterilization with Essure performed in an operating room
showed some savings via hysteroscopy [21]. A retrospective cohort
study of sterilizations showed total costs for laparoscopy and hysteros-
copy to be US $2880 and US $2700, respectively. None of these studies
factored in the opportunity cost savings realized by patients enjoying a
shorter recovery time and a quicker return to work or family.
6. Challenges, pitfalls, unique features
6.1. Permanency
Essure sterilization is permanent. Unlike postpartum or laparoscopic
tubal ligation, tubal reversal after Essure is not feasible. One can argue
whether this represents a reason toavoid this sterilization technique. But,
the information is certainly an important part of preoperative counseling.
6.2. Pregnancy in the presence of micro-coils
Pregnancy outcomes look favorable when pregnancy occurs—
planned or unplanned—in the presence of the Essure micro-coils.
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been used to treat hydrosalpinx with subsequent in vitro fertiliza-
tion [22]. Unpublished data regarding the pregnancies reported
to Conceptus suggest spontaneous abortion rates and pregnancy
complication rates are not higher in the presence of the micro-
coils.
6.3. Uterine instrumentation after Essure
Blind uterine instrumentation after Essure might displace a micro-
coil. Currently, it is prudent to perform any cavity instrumentation after
Essure via direct hysteroscopic visualization. This is a topic ripe for
investigation. Properly-placed coils become encapsuled by endometrial
tissue [23]. The fear of disrupting the micro-coils and causing harm or
altering contraceptive efficacy may turn out to be unwarranted.
6.4. Endometrial ablation
There is considerable experience with concomitant Essure–
endometrial ablation procedures, and with endometrial ablation
performed after Essure is confirmed byHSG [24–26]. Concern continues
over the application of electrosurgical energy in the presence of Essure
micro-coils. For instance, endometrial resection or ablation, or global
ablation via radiofrequencyenergy (Novasure) poses a theoretical, if not
a demonstrable, risk of conducting energy toward the bowel. Thermal
global ablation was initially marketed as a viable procedure to perform
concomitantly with Essure. Concern over the ability to interpret the
post-Essure hysterosalpingogramafter endometrial ablation has led to a
change in FDA labeling. Essure placement and confirmation should be
accomplished prior to endometrial ablation.
6.5. Alternatives to HSG
There are several ways to view the confirmatory hysterosalpin-
gogram, which continues to be recommended after Essure. One
viewpoint sees hysterosalpingogram as a “test of cure,” much like
the semen analysis that is routinely done after vasectomy to dem-
onstrate sterility. However, HSG adds to the cost of this procedure
and is inconvenient for the patient. One retrospective review of
patient compliance in a general clinic population showed that only
12.7% of patients presented to undergo HSG after the successful
bilateral Essure placement [27]. Several alternatives to HSG have
been advocated. Since studies to date suggest that all tubes are
eventually (at 6 months, if not at 3 months) occluded when the
micro-coils are located properly, imaging may only need to dem-
onstrate implant location. Plain films, standard sonography, and
contrast infusion sonohysterography have been applied as alter-
natives to confirmation using HSG. However, studies to date have
not been powered to be able to demonstrate that any alternative
imaging technique can replace HSG [28–30]. Indeed, one cannot
make definite conclusions about exactly what it means to see tubal
occlusion or patency using HSG after Essure. Pregnancy after an
unconfirmed Essure placement looks like it is exceedingly rare.
Commercial use and more studies will shed light on whether HSG is
any more necessary after hysteroscopic sterilization than it is after
laparoscopic sterilization.
7. Other hysteroscopic options: Adiana transcervical
sterilization system
This promising procedure causes tubal occlusion through a com-
bination of radio-frequency tubal endocoagulation and the implanta-
tion of a silicone matrix [31,32]. Adiana (Hologic; Bedford, MA, USA)
received CE marking approval in January 2009, allowing it to be
marketed to European Union countries. FDA approval for marketing in
the United States followed in July, 2009.7.1. Design: Placement
In the Adiana system the delivery catheter is introduced through a
5-Fr hysteroscopeworking channel. Proper depth of placementwithin
the cannulated tube is accomplished with visual cues on the delivery
catheter. A bipolar electrode array applies 60 seconds of RF energy
(3 Watts) to achieve a temperature of 64 ºC. After endocoagulation,
a porous cylindrical matrix of silicone (3.5 mm long, 1.5 mm in
diameter) is released in apposition within the treated area and the
catheter is removed. Tissue in-growth occurswithin thematrix, which
leads to tubal occlusion. The patient cannot rely on the procedure for
contraception until occlusion is confirmed by HSG 3 months after the
procedure. Unlike the Essure micro-coils, the Adiana silicone matrix is
not radio opaque. Ultrasound has been used to visualize the matrix.
7.2. Literature
The Phase III trial had 645women in the intent-to-treat group [15].
Bilateral placement was achieved in 95%. A total of 570 out 645
(88.4%) complied with follow-up and were ultimately able to rely on
Adiana. Similar to Essure, about 3% had to wait 6 months to see tubal
occlusion demonstrated using HSG. Eleven pregnancies occurred
during the first 15 months of postprocedure follow-up. Of these 11, 6
occurred in women who complied with follow-up and were told they
could rely on the device. Five pregnancies occurred in patients who
experienced placement failure or who did not use alternative contra-
ception prior to undergoing HSG. The 6 pregnancies indicated a 1-year
failure rate of 1.1%. Long-term data are not yet available, but the data
submitted to the FDA indicates 4 other pregnancies from the group
who were told they could rely on Adiana, for a total of 10. This
increases the failure rate to 1.8% at 2 years.
7.3. Adverse events
Patients reported high satisfaction rates for this 12-minute out-
patient procedure. Same-day and 1-year adverse events were minor,
with the exception of one ectopic pregnancy among the patients
instructed to rely on Adiana.
7.4. Hysterosalpingography
Three of the 6 pregnancies among compliant patients at 1 year of
follow-up are attributed to misinterpretation of the hysterosalpingo-
gram. This underscores the problematic nature of HSG to confirm the
ability to recommend reliance after hysteroscopic sterilization. It is
not clear whether HSG-alternatives may be viable options after
Adiana, as they have been proposed after Essure.
7.5. Summary
Long-term data will help define the efficacy of Adiana at pre-
venting pregnancy. It looks like it may be another safe, effective
outpatient transcervical sterilization option. However, initial data are
disappointing when comparing Adiana with laparoscopic sterilization
or to Essure.
8. Conclusion
Clinical data and real-world experience indicate that a viable
transcervical sterilization technique finally exists. Recent data suggest
that patients and surgeons are choosing hysteroscopic sterilization over
laparoscopic and postpartum sterilization [33]. The relative safety of
hysteroscopic tubal occlusion over methods that require abdominal
incision offers a compelling reason for sterilization patients to choose
hysteroscopy. The techniques currently available do pose some new
challenges. Although the devices are relatively expensive, the ability to
84 R.D. Smith / International Journal of Gynecology and Obstetrics 108 (2010) 79–84place the implants in the office setting offers a cost-saving opportunity.
This will pave the way for making this long-term birth control method
an option worldwide.
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